Annals of Oncology Advance Access originally published online on September 13, 2006
Annals of Oncology 2007 18(1):116-121; doi:10.1093/annonc/mdl316
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
hematologic malignancies |
A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150
1 Department of Medical Oncology, Cross Cancer Institute, Edmonton, Alberta
2 Juravinski Cancer Centre, Hamilton, Ontario
3 University Health Network, Princess Margaret Hospital, Toronto, Ontario
4 BC Cancer Agency, Vancouver Clinic, Vancouver, British Columbia
5 National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada
6 Cancer Therapy Evaluation Program, National Cancer Institute United States, Bethesda, MD, USA
* Correspondence to: Dr E. A. Eisenhauer, Director, IND Program, National Cancer Institute of Canada Clinical Trials Group, Queen's University, 10 Stuart Street, Kingston, Ontario K7L 3N6, Canada. Tel: +1 613 533 6430; Fax: +1 613 533 2411. E-mail: eeisenhauer{at}ctg.queensu.ca
Background: We evaluated the activity and toxic effects of bortezomib in patients with mantle cell lymphoma.
Patients and methods: Thirty patients, including 29 eligible patients, were enrolled; 13 had received no prior chemotherapy. The dose of bortezomib was 1.3 mg/m2 given on days 1, 4, 8 and 11 every 21 days. Response was assessed according to the International Workshop Criteria for non-Hodgkin's lymphoma and toxicity graded using the National Cancer Institute Common Toxicity Criteria version 2.0.
Results: There were 13 responding patients (46.4%; 95% confidence interval = 27.5% to 66.1%), including one unconfirmed complete remission. The median response duration was 10 months. Response rates were similar in previously untreated (46.2%) and treated (46.7%) patients. Neurological toxicity and myalgia led to treatment discontinuation in 10 patients after two to seven treatment cycles. Five serious adverse events (including two deaths) associated with fluid retention were observed in the first 12 patients. We subsequently excluded patients with baseline effusions, dyspnea or edema; no further events were seen.
Conclusions: Bortezomib is active in treating patients with mantle cell lymphoma. While cumulative neuromuscular toxic effects limited therapy duration and specific issues related to fluid retention require further evaluation, continued study of this drug in combination regimens is warranted.
Key words: Bortezomib, mantle cell lymphoma
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in Ann Oncol:
- in this issue
Ann Oncol 2007 18: 1.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  A. Delmonte, M. Ghielmini, and C. Sessa Beyond Monoclonal Antibodies: New Therapeutic Agents in Non-Hodgkin's Lymphomas Oncologist, May 1, 2009; 14(5): 511 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Goy, S. H. Bernstein, B. S. Kahl, B. Djulbegovic, M. J. Robertson, S. de Vos, E. Epner, A. Krishnan, J. P. Leonard, S. Lonial, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study Ann. Onc., March 1, 2009; 20(3): 520 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ruan, K. Hajjar, S. Rafii, and J. P. Leonard Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma Ann. Onc., March 1, 2009; 20(3): 413 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Z. Orlowski and D. J. Kuhn Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade Clin. Cancer Res., March 15, 2008; 14(6): 1649 - 1657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Perez-Galan, G. Roue, N. Villamor, E. Campo, and D. Colomer The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak Blood, May 15, 2007; 109(10): 4441 - 4449. [Abstract] [Full Text] [PDF]
|
|